1. Pier Meroni, Maria Orietta Borghi

    Review 3: "Anti-PF4 levels of patients with VITT do not reduce 4 months following AZD1222 vaccination"

    This paper claims that, although anti-PF4 antibody levels remain high in VITT patients months after follow up, it is not associated with increased platelet activation Reviewers found it timely and reliable but in need of minor revisions on its methodology and discussion.

    Read the original source
    Was this evaluation helpful?
  2. Strength of evidence

    Reviewers: Kochawan Boonyawat (Mahidol University) | 📗📗📗📗◻️
    Helmuth Haslacher, Thomas Perkmann (Medical University of Vienna) | 📒📒📒◻️◻️
    Pier Meroni, Maria Orietta Borghi (Fondazione Istituto Auxologico Italiano) |📗📗📗📗◻️

    Read the original source
    Was this evaluation helpful?
  3. Kochawan Boonyawat

    Review 1: "Anti-PF4 levels of patients with VITT do not reduce 4 months following AZD1222 vaccination"

    This paper claims that, although anti-PF4 antibody levels remain high in VITT patients months after follow-up, it is not associated with increased platelet activation Reviewers found it timely and reliable but in need of minor revisions on its methodology and discussion.

    Read the original source
    Was this evaluation helpful?
  4. Helmuth Haslacher, Thomas Perkmann

    Review 2: "Anti-PF4 levels of patients with VITT do not reduce 4 months following AZD1222 vaccination"

    This paper claims that, although anti-PF4 antibody levels remain high in VITT patients months after follow-up, it is not associated with increased platelet activation Reviewers found it timely and reliable but in need of minor revisions on its methodology and discussion.

    Read the original source
    Was this evaluation helpful?
  5. SciScore for 10.1101/2021.08.17.21262138: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    EthicsConsent: Informed consent was provided by the patients or by their next of kin in those who lacked capacity.
    Field Sample Permit: Collection of blood from these patients (including those lacking capacity) was approved under research ethics granted to the University of Birmingham Human Biomaterial Resource Centre (North West – Haydock Research Ethics Committee, reference: 15/NW/0079, amendment 3, 19/11/2018).
    IRB: Collection of blood from these patients (including those lacking capacity) was approved under research ethics granted to the University of Birmingham Human Biomaterial Resource Centre (North West – Haydock Research Ethics Committee, reference: 15/NW/0079, amendment 3, 19/11/2018).
    IACUC: Ethical approval for collecting blood from healthy volunteers was granted by Birmingham University Internal Ethical Review Committee (reference: ERN_11-0175, assessed 22/3/2021).
    Sex as a biological variablenot detected.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    All studies were performed in line with the Declaration of Helsinki. Materials: PF4 was from Chromatec GmbH (Greifswald, Germany), collagen-related-peptide (CRP) was from CambCol Ltd (Ely, UK), FITC-conjugated mouse anti-human CD32a antibody was from BD Pharminogen (Wokingham, UK), FITC-conjugated IgG1 control mouse antibody was from Dako (Santa Clara, CA).
    CRP
    suggested: None
    IgG1
    suggested: None
    PF4 antibody testing: Testing for anti-PF4/heparin antibodies was done using an anti-PF4/heparin enzymatic immunoassay (EIA, LIFECODES PF4 enhanced assay; Immucor GTI Diagnostics) for IgG, IgM, and IgA PF4-heparin antibodies.
    anti-PF4/heparin
    suggested: None
    IgA PF4-heparin
    suggested: None
    Washed platelets (2×107) were stained for 30 min with mouse anti-human CD32a antibody or FITC control antibody.
    anti-human CD32a
    suggested: None

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    Results from scite Reference Check: We found no unreliable references.


    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

    Read the original source
    Was this evaluation helpful?